

Evaluation of serum levels of Proinflammatory Cytokines IL-8, IL-17, and IL-22 in *Helicobacter pylori* infection and their association with the degree of gastritis histopathology in a sample of Iraqi patients

Miriam Jasim Shehab*¹  , Batool Mutar Mahdi²  , Reem Husam Al-Tabra¹   and Dhuha Salim Namaa¹  

¹Forensic DNA Center for Research and Training, Al-Nahrain University, Baghdad, Iraq.

²Department of Microbiology, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq.

*Corresponding Author.

Received 19/02/2023, Revised 09/05/2023, Accepted 11/05/2023, Published 20/06/2023



This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/).

Abstract

Gastritis can be defined as histological inflammation of the gastric mucosa. It can be classified according to the time course of the disease as acute or chronic, histological findings, anatomic location, and pathological mechanisms. The objective of this study was to evaluation of serum levels of the proinflammatory cytokines IL-8, IL-17 and IL-22 in *Helicobacter pylori* infection and their association with the degree of gastritis histopathology in a sample of Iraqi patients. The case-control prospective study consists of 60 patients who attended the Gastrointestinal Tract Center at Al-Kindy Teaching Hospital during the period from December 2019 to April 2020. In addition, the control group included 60 apparently healthy individuals. Biopsies from the gastric antrum and/or body mucosa were used to assess the severity of chronic inflammation, neutrophil infiltration, atrophy, intestinal metaplasia. Serum samples were obtained to determine *H. pylori* infection, circulating interleukin (IL)-8, IL-17, and IL-22. Results showed that the Patients' ages with gastritis ranged from 18-75 years. The body mass index revealed that 33.33% of the patients were obese and 35% of them were overweight. Most of the patients with active chronic gastritis and superficial chronic gastritis had positive titers for anti-*H. pylori* IgG antibody (167.89 ± 3.18 IU/ml) and (150.74 ± 1.45 IU/ml) respectively, which was significantly different from the control group (4.36 ± 0.29 IU/ml) ($P=0.0001$). Histopathological analysis showed that all subjects experienced chronic inflammation, while neutrophil infiltration was found 36.66% and there was significant association between serum levels of IL-8, IL-17, and IL-22 with a degree of chronic inflammation and neutrophils infiltration. In conclusion, the most common cause of gastritis was *H. pylori* with histopathological lesions, showing neutrophils infiltration and chronic gastric mucosal inflammation associated with increased levels of IL-8, IL-17, and IL-22 in serum.

Keywords: Biopsies, Cytokines, Gastritis, Histopathology, *H. pylori*.

Introduction

Gastritis can be defined as histological inflammation of the gastric mucosa. It can be classified according to the time course of the disease whether acute or chronic, histological findings, anatomic location, and pathological mechanisms. The most common cause

of gastritis is *Helicobacter pylori* (*H. pylori*) infection, tobacco smoking, alcohol, use of non-steroidal anti-inflammatory drugs (NSAIDs) or steroids, autoimmune gastritis, collagenous gastritis, sarcoidosis, eosinophilic gastritis, and lymphocytic

gastritis¹. Patients with chronic gastritis may end up with Gastric atrophy (GA), gastric ulcer, and metaplasia in the intestine of the gastric mucosa (GIM) and may develop gastric adenocarcinoma (GC), which is the fifth most common cancer all over the world and causes mortality as a result of delayed diagnosis². *H. pylori* may introduce alterations in its genetics, produce many virulence factors, toxins, and proteins, and stimulates miscellaneous adaptation processes throughout its adhesion and colonization. In addition to that, it changes its shape from spiral to coccoid to persist in the gastrointestinal tract (GIT). Therefore, the pathogenicity and virulence of *H. pylori* are sophisticated interactions among virulence factors, host, and environmental factors³. The host's immune responses play an important role in controlling the infection. Interleukine-8 (IL-8) is an important mediator in *H. pylori*-associated gastritis⁴. In infected individuals, The T-helper (Th)-CD4+ lymphocytes in the gastric lamina propria become polarized and hyporesponsive by Th1/Th17 cells that are under the control of Treg (CD25+) cells. Th17 in the gastric mucosa plays an important role in gastric pathogenesis via secretion of IL-17 that affects the activity of antimicrobials and the immune response inside the gut environment⁵. On the other hand, IL-22 is a multifunctional cytokine that helps to maintain tissue homeostasis and regulate immune responses. Its role in *H. pylori* infection is not well understood, but it is known to play a critical role in tissue repair and regeneration, especially in barrier tissues like the gut⁶. This study was designed to an evaluation of serum levels for the proinflammatory cytokines IL-8, IL-17, and IL-22 in *Helicobacter pylori* infection and their association with the degree of gastritis histopathology.

Patients and methods:

This is a case-control prospective study including 60 patients, 30 males and 30 females who attended the Gastrointestinal Tract Center at Al-Kindy Teaching Hospital during the period from December 2019 to April 2020 with the cooperation of the medical and nursing staff of the Endoscopy Unit. The inclusion criteria were patients who were complaining of epigastric pain, dyspepsia, nausea, vomiting, and upper-gastrointestinal bleeding presenting as hematemesis and/ or Malena. The exclusion criteria were patients with carcinoma of the stomach and esophagus. The patients who underwent endoscopic examination were kept fasting for at least 8 hours and the examination was performed under local pharyngeal anesthesia by

using fiber optic endoscope: GIF-H260; Olympus, Tokyo, Japan display screen; Olympus OEV-261H liquid crystal display monitor; Olympus, Tokyo, Japan for diagnosis confirmation with biopsies for histopathological studies. The second group was the control group that included 60 apparently healthy individuals that matched the gastritis patients in sex and age, but without any gastric disorders or complaints.

Ethical clearance was obtained from Al-Kindy Teaching Hospital's Scientific and Ethical Committee as well as Al-Kindy College of Medicine. Informed consent was obtained from each participant prior to the commencement of the study.

Gastritis histological analysis

Sixty biopsies of the mucosa of the gastric antrum and stomach body were used to determine the degree of histological gastritis. Patients' biopsy samples were first fixed in 10% formalin, and then they were embedded in paraffin. After that, they were stained using Hematoxylin- Eosin and examined by the pathologists of Al-Kindy Teaching Hospital in a blinded technique. The histopathological study included: the degree of neutrophils infiltration, chronic gastric mucosal inflammation, mucosal atrophy, and intestinal metaplasia according to the most recent Sydney System, they were graded as (0) normal, (1) mild, (2) moderate, and (3) severe⁷.

Serological examination

One hundred twenty sera samples were collected from both gastritis patients and apparently healthy individuals for serological examination. Enzyme-linked immunosorbent assay kit (Immunolab, Germany) used for the determination of the quantity of anti- *H. pylori* IgG antibodies in the sera of the study groups. Serum levels of IL-8 was measured according to manufacturer instructions, using ELISA kit from Beckman Coulter Marseille, France. While, ELISA kits of IL-17 and IL-22 were obtained from Al-shkairate Company, Jordon.

Statistical Analysis:

Statistical Analysis System (SAS) program, 2018 was used in this study. The Least Significant Difference (LSD) test (Analysis of Variation, ANOVA) was performed to compare between means. The Chi-square test was used to determine an association between categorical variables in a significant way (0.05 and 0.01 probability). In this study, the odd ratio and confidence interval were estimated.

Results

This study included 60 patients with gastritis confirmed by gastroscopy and histopathology. Their ages ranged from 18-75 years old. Most of them were between 30-50 years old (56.67%) which was not significantly different from the control group (53.33%) as shown in fig.1. Male to female ratio was 1:1(50% males and 50% females) is nearly frequency- matched with the control group as demonstrated in fig.2. Regarding body mass index, Fig.3 illustrated that the percentage of individuals that have a normal weight (18.5-25) and obese (BMI more than 30) tended to be lower in the control group when compared with the patients' group (25% versus 31.67% and 31.67% versus 33.33%, respectively). In contrast, the control group tended to be more overweight (25.1-30) in comparison with the patients' group (43.33% versus 35%, respectively) but the differences did not reach the significance level. The main cause of gastritis in those patients was infection with *H. pylori*. Most of the patients with active chronic gastritis and superficial chronic gastritis had positive titers for anti-*H. pylori* IgG antibody (167.89 ± 3.18 IU/ml) and (150.74 ± 1.45 IU/ml) respectively, which was significantly different from the control group (4.36 ± 0.29 IU/ml) ($P=0.0001$) as shown in table 1.

Gastric biopsies were taken from the patients and sent for histopathologic study. The most common

findings were moderate chronic gastric mucosal inflammation seen in 29 (48.33%) of the cases followed by mild chronic gastric mucosal inflammation 21 (35%) and severe gastric mucosal inflammation 10 (16.66) as shown in Table 2. Furthermore, histological analysis confirmed that only 22 (36.66%) of cases were infected with *H. pylori* as presented in table 2.

Concerning cytokines levels of IL-8, IL-22, and IL-17 in patients with gastritis, there was a significant increase ($P= 0.0001, 0.0001, \text{ and } 0.0062$) in the serum ($336.95 \pm 19.41, 38.77 \pm 1.01, 18.84 \pm 0.16$ pg/ml), respectively, as compared with the control group ($122.48 \pm 12.07, 17.69 \pm 1.34, \text{ and } 14.09 \pm 0.8$ pg/ml) as shown in Table 3. In addition, analysis association between cytokines serum levels with the degree of gastritis histopathology revealed that, the percentage of patients that showed increased in the cytokines levels of IL-8, IL-17, and IL-22 were significantly associated with moderate and severe chronic inflammation [OR (95% CI): 1.26 (0.82-2.15); 1.33:(0.86-2.09) and 1.07:(0.72-1.87) respectively, $P \leq 0.05$] and neutrophil infiltration of gastric mucosa [OR (95% CI) were 1.74 (0.92-3.05); 2.19:(1.15-4.22) and 1.56: (1.02-3.97) respectively, $P \leq 0.01$] as demonstrated in Table 4.




Figure 1. Distribution of study samples based on age groups.




Figure 2. Distribution of study samples based on gender




Figure 3. Distribution of study samples based on Body Mass Index (BMI).

Table 1. The mean level of anti-*H. pylori* IgG antibody concentration in study groups.

Study groups	Number	Level of anti- <i>H. pylori</i> IgG antibody (IU/ml) (Mean \pm SD)	P-value
Active chronic gastritis	22	167.89 \pm 3.18 a	0.0001 **
Superficial chronic gastritis	38	150.74 \pm 1.45 a	
Control group	60	4.36 \pm 0.29 b	

Means with different letters in the same column were significantly different.

** (P \leq 0.0001).

Table 2. Histopathologic grading of gastritis according to Sydney System.

Histological results	Normal (0)		Mild (1)		Moderate (2)		Sever (3)		Total
	No.	(%)	No.	(%)	No.	(%)	No.	(%)	
Neutrophil infiltration	38	(63.33)	12	(20)	6	(10)	4	(6.67)	22 (36.66)
Chronic gastric mucosal inflammation	0	0	21	(35)	29	(48.33)	10	(16.66)	60 (100%)
Mucosal atrophy	0	0	0	0	0	0	2	(3.33)	2 (3.33)
Intestinal metaplasia	0	0	0	0	0	0	0	0	0
H. pylori positive by histopathology	38	(63.33)	10	(16.66)	7	(11.66)	5	(8.33)	22 (36.66)

Table 3. Cytokines levels in patients and control groups.

Cytokines	Serum level (pg/ml)		P-value
	Gastritis patients	Control group	
IL-8	336.95± 19.41	122.48± 12.07	0.0001 **
IL-17	38.77 ± 1.01	17.69 ± 1.34	0.0001 **
IL-22	18.84 ± 0.16	14.09 ± 0.8	0.0062 **

** (P≤0.01).

Table 4. Association among cytokines levels of IL-8, IL-17, IL-22 and degree of chronic inflammation and neutrophil infiltration.

Cytokines		Chronic inflammation			P-value	OR (95% CI)	Neutrophil infiltration		P-value	OR (95% CI)
		N. (%)		P-value			N. (%)			
		Normal + mild	Moderate + sever				Normal + mild	Moderate + sever		
IL-8	High	9 (15%)	22 (36.66%)	0.037 *	1.26 (0.82-2.15)	24 (40%)	7 (11.66%)	0.0052 **	1.74 (0.92-3.05)	
	Low	12 (20%)	17 (28.33%)			26 (43.33%)	3 (5%)			
IL-17	High	7 (11.66%)	19 (31.66%)	0.039 *	1.33 (0.86-2.09)	17(28.33%)	6 (10%)	0.0006 **	2.19 (1.15-4.22)	
	Low	14 (23.33%)	20 (33.33%)			33 (55%)	4(6.66%)			
IL-22	High	14(23.33%)	23 (38.33%)	0.041 *	1.07 (0.72-1.87)	21 (35%)	6 (10%)	0.0084 **	1.56 (1.02-3.97)	
	Low	7(11.66%)	16 (26.66%)			19 (31.66%)	4 (6.66%)			

* (P≤0.05), ** (P≤0.01).

Discussion

In this study, the highest incidence of gastritis was observed to occur between the third and fifth decades. Age can be a crucial factor for having gastritis due to thinning stomach lining with aging because of aging is related to a decreased rate of gastric epithelial cell turnover and a decreased ability to repair the gastric mucosa due to decreased levels

of prostaglandin in the gastric mucosa. Additionally, lifestyle factors such as stress, smoking, and diet may contribute to the development of gastritis. This result agrees with other studies that have shown that aging is associated with inflammatory changes in the gastric body, which can also contribute to the development of gastritis^{8, 9}. In the present study,

serological tests for *H. pylori* IgG showed the highest positive frequency when compared with the histological examination that showed only 22 (36.66%) from cases were infected with *H. pylori* and IgG antibodies titer was higher in active chronic gastritis than superficial chronic gastritis. Previous studies reported that the prevalence of *H. pylori* infection increased in the Middle East region, and the rate was more in subjects with gastritis and this prevalence was varied between studies performed in different countries and within the same country. The serological index of IgG antibodies cannot predicate whether the individuals have a previous or current infection. IgG antibodies can be found even after the bacteria clearance and IgG level could be decreased to 40-50% by 6-month post-treatment, and only 25% of successfully treated patients show complete disappearances of IgG¹⁰⁻¹³.

One of the risk factors for gastritis is high body mass index as seen in this research (BMI of more than 30 kg/ m² was associated with gastritis 33.33%). This study is in accordance with previous studies illustrated that obese patients had higher *H. pylori* infection and gastritis than lean patients with BMI less than 25 kg/m². High BMI leads to lipid peroxidation, oxidative stress, decreased antioxidant activity all of which led to oxidative DNA damage that increased the risk of gastric cancer¹⁴⁻¹⁶. The histopathological tests showed that all subjects experienced chronic inflammation, while neutrophil infiltration was found 36.66% and atrophy and intestinal metaplasia were not found in the present study. The degree of gastritis histopathology results was varied among studies^{17, 18}. This difference may be due to patient selection, duration of the disease, underlying causes, race of the patients included in the study, sample size, and the timing of biopsies during the course of the disease. The mucosa of stomach

Conclusion

The most common cause of gastritis was *H. pylori* with histopathological lesions showing neutrophil infiltration and chronic gastric mucosal

corpus either undergo superficial injury that heals through histopathologic changes of surface cells like foveolar hyperplasia or it may suffer a deep injury like chronic inflammation caused by *H. pylori* leading to pyloric pseudopyloric metaplasia, loss of parietal cells that secrete acids i.e. atrophic gastritis, foveolar cells expansion, and turning of chief cells which secretes enzymes in the deep antral gland that is similar to mucous cells. Chief cells can be reprogrammed into paligenosis and mucus secreting spasmolytic polypeptide which expresses metaplasia cells stimulated by IL-13 secreted from innate lymphoid cells (ILC2s)¹⁸. This study demonstrated the significant elevation in the levels of IL-8, IL-17 and IL-22 as compared with control samples. Compatible with a previous study, the present study demonstrated that *H. pylori* stimulate Th CD4+ cells and Th17 to secrete proinflammatory cytokines IL-17A, IL-17F, IL-21 and IL-22, which have antimicrobial response and control bacterial colonization. IL-22 and IL-17 act synergistically in the stimulation of chemokines and antimicrobials like lipocalin (LCN), IL-8 and some β -defensins within gastric epithelial cells that inhibit growth of *H. pylori*¹⁹. Infection with *H. pylori* induces IL-17 secretion in the mucosa of the stomach that induces IL-8 secretion via ERK 1/2 MAP kinase pathway activation. IL-8 works by attracting neutrophil to induce inflammation, while T regulatory cells (Tregs) works on suppressing the reaction of mucosal inflammation initiated by IL-17. Gastric inflammation is stimulated by host factors like IL-6, IL-1 β , TGF- β 1, tumor necrosis factor TNF- α , IL-22, IL-21, IL-18 and IL-17, and the *H. pylori* factors like vacuolating cytotoxin A (vacA) and proteins cytotoxin associated gene A (cagA)²⁰. So, inhibition of these cytokines may be used as a potential therapeutic opportunity in the treatment²¹.

inflammation associated with increased levels of IL-22, IL-8, and IL-17 in the serum.

Acknowledgment

Many thanks to the staff of the Gastrointestinal Tract Center at Al-Kindy Teaching Hospital.

Author's Declaration

- Conflicts of Interest: None.
- We hereby confirm that all the Figures and Tables in the manuscript are ours. Furthermore, any Figures and images that are not ours have been included with the necessary permission for re-publication, which is attached to the manuscript.
- Authors sign on ethical consideration's approval.
- Ethical Clearance: The project was approved by the local ethical committee in University of Baghdad.

Author's Contribution Statement

M.J.Sh. devised the project, samples collection and responsible on carried out ELISA technique. B.M.M.

interpretation of histological reports and writing the manuscript. R.H. and Dh. S.N. data analytic.

References

1. Azer SA, Akhondi H. Gastritis. In: StatPearls. Treasure Island (FL): Stat Pearls Publishing; July 4, 2022. PMID: 31334970, Bookshelf ID: NBK544250.
2. Raza M, Bhatt H. Atrophic Gastritis. In: StatPearls. Treasure Island (FL): Stat Pearls Publishing; August 8, 2021.
3. Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. *Braz J Microbiol.* 2022;53(1):33-50. <https://doi.org/10.1007/s42770-021-00675-0>
4. Ruggiero P. Helicobacter pylori and inflammation. *Curr Pharm Des.* 2010;16(38):4225-4236. <https://doi.org/10.2174/138161210794455117>.
5. Bagheri N, Razavi A, Pourgheysari B, et al. Up-regulated Th17 cell function is associated with increased peptic ulcer disease in Helicobacter pylori-infection. *Infect Genet Evol.* 2018;60:117-125. <https://doi.org/10.1016/j.meegid.2018.02.020>
6. Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: driving protection and pathology. *Eur J Immunol.* 2017;47(4):607-614. <https://doi.org/10.1002/eji.201646723>.
7. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol.* 1996;20(10):1161-81.
8. Kako S, Iwaya Y, Nagaya T, et al. Clinicopathological features of nodular gastritis in three classes of age. *Helicobacter.* 2021;26(6):e12845. <https://doi.org/10.1111/hel.12845>
9. Pilotto A and Franceschi M. Helicobacter pylori infection in older people. *World J Gastroenterol.* 2014; 20:6364-73.
10. Alsamarai AM, Thegeal F and Alobaidi AHM. Frequency of Biomarkers Positivity in Iraqi Subject with Gastritis. *Sci. Int.* 2017; 5 (2): 68-83.
11. Bionda M, Kapoglou I, Wiest R. H. pylori-assozierte Gastritis: Diagnostik, Therapie und Nachsorge [H. pylori-associated gastritis: diagnostic, treatment and surveillance]. *Ther Umsch.* 2020;77(4):127-131. <https://doi.org/10.1024/0040-5930/a001167>
12. Pandya HB, Patel JS, Agravat HH, Singh NKR. Non-Invasive Diagnosis of Helicobacter pylori: Evaluation of Two Enzyme Immunoassays, Testing Serum IgG and IgA Response in the Anand District of Central Gujarat, India. *J Clin Diagn Res.* 2014; 8(6): 12-15.
13. Leja M, Grinberga-Derica I, Bilgiler C, Steininger C. Review: Epidemiology of Helicobacter pylori infection. *Helicobacter.* 2019 Sep;24 Suppl 1:e12635. <https://doi.org/10.1111/hel.12635>. PMID: 31486242
14. Al-Thuwaini TM. Body mass index and shortened telomere length in middle-aged female and male Running Head : Middle-aged and shortened telomere length. *Baghdad Sic J.* 2022;19(2):246-254. <http://dx.doi.org/10.21123/bsj.2022.19.2.0246>
15. Al-Zubaidi AM, Alzobydi AH, Alsareii SA, Al-Shahrani A, Alzaman N, Kassim S. Body Mass Index and Helicobacter pylori among Obese and Non-Obese Patients in Najran, Saudi Arabia: A Case-Control Study. *Int J Environ Res Public Health.* 2018;15(11):2586. Published 2018 Nov 19. <https://doi.org/10.3390/ijerph15112586>
16. Mustaf AJ and Ismail PA. Association of potent inflammatory Cytokine and Oxidative DNA Damage Biomarkers in Stomach cancer patients. *Baghdad Sic J.* 2022, 19(6): 1313-1325. <https://dx.doi.org/10.21123/bsj.2022.6589>
17. Siregar GA, Halim S and Sitepu RR. Serum TNF- α , IL-8, VEGF Levels in Helicobacter pylori Infection and Their Association with Degree of Gastritis. *Acta Med Indones-Indones J Intern Med.* 2015; 47(2):120-126.
18. Goldenring JR, Mills JC. Cellular Plasticity, Reprogramming, and Regeneration: Metaplasia in the Stomach and Beyond. *Gastroenterology.* 2022;162(2):415-430. <https://doi.org/10.1053/j.gastro.2021.10.036>
19. Dixon BR, Radin JN, Piazuolo MB, Contreras DC, Algood HM. IL-17a and IL-22 Induce Expression of Antimicrobials in Gastrointestinal Epithelial Cells and

- May Contribute to Epithelial Cell Defense against *Helicobacter pylori*. PLoS One. 2016;11(2):e0148514. <https://doi.org/10.1371/journal.pone.0148514>
20. Della Bella C, Antico A, Panozzo MP, Capitani N, Petrone L, Benaglio M, et al. Gastric Th17 Cells Specific for H+/K+-ATPase and Serum IL-17 Signature in Gastric Autoimmunity. Front Immunol. 2022;13:952674. <https://doi.org/10.3389/fimmu.2022.952674>. PMID: 35911678; PMCID: PMC9328118.
21. Nguyen PM, Putoczki TL. Could the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer?. Cytokine. 2019;118:8-18. <https://doi.org/10.1016/j.cyto.2018.01.008>

تقييم مستويات السيتوكينات الموالية للالتهاب انترلوكين 8، انترلوكين 17 وانترلوكين 22 مع الإصابة ببكتريا *Helicobacter pylori* ودرجة التهاب المعدة في عينة من المرضى العراقيين

مريم جاسم شهاب¹، بتول مطر مهدي²، ريم حسام الطبره¹ وضحى سالم نعمة¹

¹ مركز الدنا العدلي للبحث والتدريب، جامعة النهرين، بغداد، العراق.
² قسم الاحياء المجهرية، كلية طب الكندي، جامعة بغداد، بغداد، العراق.

الخلاصة

يعرف التهاب المعدة بأنه التهاب نسيجي للطبقة المخاطية المبطنة للمعدة ويصنف اعتمادا على مدة المرض إلى التهاب حاد أو مزمن، وكذلك اعتمادا على النتائج النسيجية والموقع التشريحي والإمراضية. هدفت الدراسة الحالية إلى تقييم مستويات المصل للسيتوكينات الموالية للالتهاب انترلوكين 8، انترلوكين 17 وانترلوكين 22 في الإصابة ببكتريا *H. pylori* وارتباطها مع درجة التهاب المعدة في عينة من المرضى العراقيين. تضمنت مجموعة الدراسة 60 مريضا من بين الأشخاص الذين يعانون من أعراض التهاب المعدة وكانوا يقصدون قسم تنظير الجهاز الهضمي / مستشفى الكندي التعليمي خلال الفترة من كانون الثاني 2019 إلى نيسان 2020. بالإضافة إلى مجموعة السيطرة المتكونة من 60 شخصا الذي يبدو أنهم اصحاء ظاهريا. استخدمت الخزعات النسيجية المأخوذة من الغشاء المخاطي لمنطقة غار وجسم المعدة لتحديد درجة الالتهاب النسيجي. تم الحصول على المصل لتحديد الإصابة ببكتريا *H. pylori* وقياس مستويات انترلوكين 8، انترلوكين 17 و انترلوكين 22. أظهرت النتائج أن المرضى الذين يعانون من التهاب المعدة تتراوح أعمارهم من 18-75 سنة. كشفت نتائج مؤشر كتلة الجسم أن 33.33% من المرضى يعانون من السمنة المفرطة و 35% منهم يعانون من الوزن الزائد. معظم مرضى التهاب المعدة النشط و التهاب المعدة السطحي المزمن أظهروا نتائج مصلية موجبة للأجسام المضادة لبكتريا *H. pylori* وكان معدل التركيز الاجسام المضادة للبكتريا $(167.89 \pm 3.18 \text{ IU/ml})$ و $(150.74 \pm 1.45 \text{ IU/ml})$ على التوالي مع وجود فرق عالي المعنوية $P=0.0001$ عند المقارنة مع مجموعة السيطرة $(4.36 \pm 0.29 \text{ IU/ml})$. أظهرت نتائج التحليل النسيجي ان جميع المرضى كانوا يعانون من التهاب الغشاء المخاطي المزمن، بينما 36.66% كانوا يعانون من ارتشاح خلايا الدم البيضاء المتعادلة وكان هناك ارتباط معنوي بين مستويات الانترلوكينات 8 و 17 و 22 مع درجة التهاب الغشاء المخاطي المزمن وارتشاح خلايا الدم البيضاء neutrophil. نستنتج من هذه الدراسة أن السبب الأكثر شيوعا لالتهاب المعدة هو الإصابة ببكتريا *H. pylori* مع التغيرات النسيجية المرضية والتي تضمن ارتشاح خلايا الدم البيضاء المتعادلة neutrophil و التهاب الغشاء المخاطي المزمن المرتبط مع زيادة مستويات الأنترلوكينات الموالية للالتهاب.

الكلمات المفتاحية: الخزاع النسيجية، السيتوكينات، التهاب المعدة، النسيج المرضي، الملوية البوابية.